Journal
BLOOD
Volume 113, Issue 4, Pages 945-952Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-08-172155
Keywords
-
Categories
Funding
- National Institutes of Health [RO1-HL069929, RO1-CA107096, RO1-AI080455, PO1-CA33049, T32-AI0762]
- Ryan Gibson Foundation
- Pardee Foundation
- Byrne Fund
- Emerald Foundation
- Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center
- Commonwealth Foundation
Ask authors/readers for more resources
CD4(+) interleukin-17 (IL-17)(+) T cells (Th17 cells) have been implicated in allograft rejection of solid organs and several autoimmune diseases. However, the functional role of Th17 cells in the development of acute graft-versus-host disease (GVHD) has not been well-characterized. We detected significant numbers of alloreactive CD4(+) donor T cells expressing IL-17, IL-17F, or IL-22 in the lymphoid organs of recipients of an allogeneic bone marrow transplant. We found no differences in GVHD mortality or graft-versus-tumor (GVT) activity between wild type (WT) and IL-17(-/-) T-cell recipients. However, upon transfer of murine IL-17(-/-) CD4(+) T cells in an allogeneic BMT model, GVHD development was significantly delayed behind recipients of WT CD4(+) T cells, yet overall GVHD mortality was unaffected. Moreover, recipients of IL-17 (-/-) CD4(+) T cells had significantly fewer Th1 cells during the early stages of GVHD. Furthermore, we observed a decrease in the number of IFN-gamma-secreting macrophages and granulocytes and decreased production of proinflammatory cytokines (interferon [IFN]-gamma, IL-4, and IL-6) in recipients of IL-17(-/-) CD4(+) T cells. We conclude that IL-17 is dispensable for GVHD and GVT activity by whole T cells, but contributes to the early development of CD4-mediated GVHD by promoting production of proinflammatory cytokines. (Blood. 2009;113:945-952)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available